Circulating biomarkers of lung cancer.
Research type
Research Study
Full title
Differential analysis of pulmonary venous and arterial blood for the detection of circulating biomarkers of lung cancer.
IRAS ID
193842
Contact name
Phil Crosbie
Contact email
Sponsor organisation
University Hospital of South Manchester
Duration of Study in the UK
5 years, 1 months, 0 days
Research summary
In the UK, lung cancer is responsible for one in five of all cancer deaths and has one of the poorest prognoses of all malignant diseases with 75% of patients dying within the first year and less than 10% surviving for five years. This is attributed to the late clinical presentation of the majority of patients; 80% present with locally advanced or distant metastatic disease. The National Lung Screening Trial (NLST) showed for the first time a significant reduction (20%) in lung cancer specific mortality by screening asymptomatic at risk patients with low dose CT. The limitation of radiological screening was the very high rate of false positive scans, in the order of 95% in the NLST. The development of a biomarker that could identify disease or increased susceptibility to disease would be a valuable clinical adjunct by enabling identification of early stage lung cancer or stratification of at risk individuals/populations. This would have the potential to focus screening strategies and allow earlier diagnosis with a consequent improvement in treatment outcomes.
REC name
West Midlands - Solihull Research Ethics Committee
REC reference
15/WM/0420
Date of REC Opinion
19 Nov 2015
REC opinion
Further Information Favourable Opinion